SPDR Series Trust SPDR S&P Biotech ETFSPDR Series Trust SPDR S&P Biotech ETFSPDR Series Trust SPDR S&P Biotech ETF

SPDR Series Trust SPDR S&P Biotech ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪7.82 B‬USD
Fund flows (1Y)
‪−181.19 M‬USD
Dividend yield (indicated)
0.14%
Discount/Premium to NAV
1.2%

About SPDR Series Trust SPDR S&P Biotech ETF


Issuer
State Street Corp.
Brand
SPDR
Expense ratio
0.35%
Home page
Inception date
Jan 31, 2006
Index tracked
S&P Biotechnology Select Industry
Management style
Passive
XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Equal
Weighting scheme
Equal
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of November 7, 2024
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.92%
Health Technology99.92%
Bonds, Cash & Other0.08%
Mutual fund0.06%
Miscellaneous0.03%
Stock breakdown by region
100%
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows